account_id none on file
legal_name Structure Therapeutics Inc.
ticker GPCR
cik 1888886
domain structuretx.com
linkedin_company_url https://www.linkedin.com/company/structuretx
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 6 executives 0 family 0
why_nownone on file
callsnone on file
filings
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.
filing / Aug 6, 2026 / receipt
In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures.
filing / Aug 6, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.
filing / May 7, 2026 / receipt
In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures.
filing / May 7, 2026 / receipt
(“Shanghai ShouTi”), the Company’s wholly-owned subsidiary, entered into a lease agreement for approximately 22,500 square feet of office space in Shanghai, China, for its research and development operations office, which commenced in July 2023 and will expire on December 31, 2026.
filing / May 7, 2026 / receipt
(“Structure USA”), the Company’s wholly-owned subsidiary, entered into a sublease agreement for approximately 11,800 square feet of office space located in South San Francisco, California for its corporate headquarters.
filing / May 7, 2026 / receipt
executivesnone on file
familynone on file
upcoming
changesnone on file
mcp_package_hint
slug structure-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$